Measuring HIV neutralization in a luciferase reporter gene assay

Methods in Molecular Biology

Volumn 485, Issue , 2009, Pages 395-405

  Montefiori, David C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Assay standardization; HIV vaccines; Neutralizing antibodies; Pseudovirus; Reporter gene

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LUCIFERASE;

ANIMAL; ARTICLE; CELL LINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; METABOLISM; METHODOLOGY; REPORTER GENE; SERODIAGNOSIS; STANDARD;

ANIMALS; CELL LINE; GENES, REPORTER; HIV; HIV ANTIBODIES; HUMANS; LUCIFERASES; NEUTRALIZATION TESTS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 60349089294     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-170-3_26     Document Type: Article

References (25)

1. Wyatt, R., Sodroski, J. (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-1888.
2. Lasky, L. A., Nakamura, G., Smith, D. H., et al. (1987) Delineation of a region of the human immunodeficiency virus gp120 glyco-protein critical for interaction with the CD4 receptor. Cell 50, 975-985.
3. Berger, E. A. (1997) HIV entry and tropism: the chemokine receptor connection. AIDS 11(suppl. A), S3-S16.
4. Berger, E. A., Doms, R. W., Fenyö, E.-M., et al. (1998) A new classification for HIV-1. Nature 391, 240.
5. Weissenhorn, W., Dessen, A., Harrison, S. C., et al. (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430.
6. Chan, D. C., Fass, D., Berger, J. M., et al. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273.
7. Chan, D. C., Kim, P. S. (1998) HIV entry and its inhibition. Cell 93, 681-684.
8. Salzwedel, K., Smith, E. D., Dey, B., et al. (2000) Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J. Virol. 74, 326-333.
9. McDougal, J. S., Kennedy,M. S., Orloff, S. L., et al. (1996) Mechanism of human immunodeficiency virus type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. J. Virol. 70, 5236-5245.
10. Sullivan, N., Sun, Y., Sattentau, Q., et al. (1998) CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72, 4694-4703.
11. Wei, X., Decker, J. M., Wang, S., et al. (2003) Antibody neutralization and escape. Nature 422, 307-312.
12. Platt, E. J., Wehrly, K., Kuhmann, S. E., et al. (1998) Effects of CCR5 and CD4 cell surface concentrations on infection by macrophage tropic isolates of human immunodeficiency virus type 1. J. Virol. 72, 2855-2864.
13. Wei, X., Decker, J. M., Liu, H., et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 46, 1896-1905.
14. Leitner, T., Korber, B., Daniels, M., et al. (2005) HIV-1 subtype and circulating recombinant form (CRF) reference sequences, 2005. in (T. Leitner, B. Foley, B. Hahn, P. Marx, F. McCutchan, J. W. Mellors, S. Wolinski, and B. Korber eds.), HIV Sequence Compendium 2005, pp. 41-48. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N. Mex. (http://hiv.lanl.gov).
15. Kwong, P. D., Doyle, M. L., Casper, D. J., et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682.
16. Richman, D. D., Wrin, T., Little, S. J. et al. (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc.Natl. Acad. Sci. (USA) 100, 4144-4149.
17. Haynes, B. F, Montefiori, D. C. (2006) Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5, 347-363.
18. Mascola, J. R., D'Souza, P., Gilbert, P., et al. (2005) Recommendations for the design and use of standard virus panels to assess the neutralizing antibody response elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79, 10103-10107.
19. Li, M., Gao, F., Mascola, J. R., et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125.
20. Li, M., Salazar-Gonzalez, J. F., Derdeyn, C. A., et al. (2006) Genetic and neutralization properties subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa.. J. Virol., in press.
21. Brown, B. K., Darden, J. M., Tovanabutra, S., et al. (2005) Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 (HIV-1) isolates, representing clades A, B, C, D, CRF01 -AE, and CRF02 -AG, for the development and assessment of candidate vaccines. J. Virol. 79, 6089-6101.
22. Esparza, J. and the Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. (2005) The Global HIV/AIDS Vaccine Enterprise: Scientific strategic plan. PLoS Medicine 2(2), e25.
23. Johnson, V. A., Byington, R. E. (1990) Infectivity assay (virus yield assay), in (Aldovani, A., and Walker, B. D., eds.), Techniques in HIV Research, pp71-76. Stockton Press, New York, N.Y.
24. Montefiori, D. C., Cornell, R. J., Zhou, J. Y., et al. (1994) Complement control proteins, CD46, CD55 and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205, 82-92.
25. Louder, M. K., Sambor, A., Chertova, E., et al. (2005) HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339, 226-238.